

Vascular Consideration with COVID-19 Vaccination: Clinical Case Report

M. Haj Abdo ^{a*}, Z. Yildirim-Oeguet ^a, H. Housen ^a, K. Zistler ^a,
A. Boulahdid ^a, V. Kolettas ^a, E. Kadriu ^a and K. Seidl ^a

^a The Department of Cardiology and Intensive Care, Clinic of Ingolstadt, Krumenauer Strasse 25, Ingolstadt 85049, Germany.

Authors' contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

Open Peer Review History:

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: <https://www.sdiarticle5.com/review-history/88468>

Case Study

Received 11 May 2022
Accepted 22 June 2022
Published 28 June 2022

ABSTRACT

Adverse cardiovascular side effects of the COVID -19 vaccine include myocarditis/pericarditis, vaccine induced thrombotic Thrombocytopenia (VITT) and thrombosis, which often related to low platelet levels and VITT in the setting. A 60-year-old female presented to our Emergency Department (ED) after cardiopulmonary resuscitation due to Asystole at home. The patient underwent a chest computed tomography (CT) scan that revealed bilateral pleural effusion without pulmonary embolism. The cardiovascular complications have been reported with both COVID-19 and its vaccination. The COVID-19 vaccines have adverse side effects, which are rare but also sometimes fulminant too.

Keywords: Cardiovascular side effects; COVID -19 vaccine; chest computed tomography; acute respiratory syndrome.

1. INTRODUCTION

“Coronavirus disease 2019 (COVID-19), the illness caused by severe acute respiratory Syndrome Coronavirus 2 (SARS-CoV-2) continue to cause significant morbidity and mortality over the World” [1,2].

“Globally, numerous vaccines have been developed against COVID-19. From December 2020 through March 2021, the European Medicines Agency approved four vaccines on the basis of randomized, blinded, controlled trials: two messenger RNA-based vaccines — BNT162b2 (Pfizer–BioNTech) and mRNA-1273

*Corresponding author: E-mail: moradhajabdo86@hotmail.de;

(Moderna) — that encode the spike protein antigen of SARS-CoV-2, encapsulated in lipid nanoparticles; ChAdOx1 nCov-19 (AstraZeneca), a recombinant chimpanzee adenoviral vector encoding the spike glycoprotein of SARS-CoV-2; and Ad26.COV2.S (Johnson & Johnson/Janssen), a recombinant adenovirus type 26 vector encoding SARS-CoV-2 spike glycoprotein” [3,4,5].

“Most people become Moderna and Pfizer-BioNTech, Although certainly side effect may occur, the benefit greatly outweigh the risks” [6].

“Adverse cardiovascular side effects of the COVID -19 vaccine include myocarditis/pericarditis, vaccine induced thrombotic Thrombocytopenia (VITT) and thrombosis, which often related to low platelet levels and VITT in the setting” [7,8].

“VITT is a new phenomenon with devastating effects for otherwise healthy young adults and requires a thorough risk–benefit analysis” [9]. “There may be an immune-mediated mechanism at the root of thrombosis, with protagonist antibodies against the PF4–polyanion complex. VITT-associated PF4 antibodies interact with the heparin-binding site. These antibodies are therefore independent from heparin. The immune complexes, formed from the binding of PF4 to antibodies, activate platelets through FcγRIIIa receptors, causing thrombocytopenia and thrombosis secondary to the activation of the coagulation pathway” [10,11,12].

2. CASE REPORT (HISTORY/ EXAMINATION)

A 60-year-old female presented to our Emergency Department (ED) after cardiopulmonary resuscitation due to Asystole at home. She had been having progressive shortness of breath over 2-3 Months that worsened acutely on the admission day with no significant past medical history. She got the COVID vaccination 3 times.

On arrival to ED Patient was intubated. She was afebrile. An electrocardiogram was performed, which showed sinus rhythm with a left axis, normal intervals and negative T wave over II, III, aVF and V1-4.

An arterial blood gas showed the following results: pH 6.7 (normal 7.35-7.45), pCO₂ 84

(normal 37-43 mmHg), bicarbonate 6.5 (normal 22-26 mmol/L), lactate 14 (normal 0.5-2.5 mmol/L), sodium 137 (normal 134-144 mmol/L), potassium 3.8 (normal: 3.5-5.5 mmol/L), and anion gap 21.9 mmol/L. There was an absence of ketones in the urinary dipstick, but positive for protein and glucose. Laboratory evaluation revealed markedly elevated creatinine level 2.2 (normal: 0.7-1.1 mg/dl) and high sensitive troponin-I (hs-TnI) 2480 ng/l (normal: 2.3-11.6 ng/l).

Takotsubo cardiomyopathy was ruled out through Cardiac-MRT, as seen in the MRT-Images (It was no myocardial scar) and Ventriculography (It was only a globally hypokinesia).

The patient underwent a chest computed tomography (CT) scan that revealed bilateral pleural effusion without pulmonary embolism. Coronary Angiogram was without a significant epicardial coronary artery disease. For further evaluation we measured the microcirculatory resistance (IMR=52) and coronary flow reserve (CFR =1.3) which were pathologic.

She was immediately started with Continuous Venovenous Hemodiafiltration (CVVHDF), then with the dialysis 3 times weekly for six weeks, which could be stopped, because of improvement in value of GFR, which was 61 ml/min/m², urine output > 100 ml /hour and creatinine 1.3 mg/dl.

Because of the unclear cause of her accelerated decrease in kidney function with need for the continuous dialysis a kidney biopsy was performed that showed microthrombi and lymphatic infiltrates as an expression of Vaccination Complication.

Brain CT performed on the first day of admission showed a subacute medullary lesion on the left periventricular side. The Brain MR showed multiple small subacute ischemia's, mainly in the centrum semiovale both sides.

3. DISCUSSION

“The cardiovascular complications have been reported with both COVID-19 and its vaccination. Vaccination has a significant effort on the prevention of severe SARS-CoV-19 Infection and its complications” [13].





Fig. 1. USG image 1

ID:10414121 10-Feb-2022 19:16:23 Klinikum Ingolstadt-ST58 ROUTINE AUFZEICHNEN

20-Nov-1961 (60 J.)	Vent. freq.	110	S/M
Weiblich Unbekannt	PQ-Zeit	*	ms
Zimmer:5812	QRS-Dauer	80	ms
Abt:3	QT/QTcB	294/397	ms
	PRT-Achse	* 12	108


Med: Unt.-Assistenz:
Indikation:



50mm/s 10mm/mV 40Hz 10.1.2 12SL 241 Gerät: 9 SID: 51463371 EID: EDT: AUFTR: AUFNAHME: 51463371
Seite 1 von 2

Fig. 2. ECG report 1

ID: 10414121 10-Feb-2022 19:16:23




Fortsetzung: 50mm/s

Seite 2 von 2

Fig. 3. ECG report 2

20-Nov-1961 (60 J.) Weiblich Unbekannt Zimmer:5812 Abt.3	Vent. freq. 110 S/M PQ-Zeit = ms QRS-Dauer 80 ms QT/QTc-B 294/397 ms PRT-Achse + 12 108	ID:10414121 10-Feb-2022 19:16:23	Klinikum Ingolstadt-ST58 ROUTINE AUFZEICHNEN
---	---	-------------------------------------	--

Med:
Unt.-Assistenz:
Indikation:



25mm/s 10mm/mV 40Hz 10.1.2 12SI 241 Gerät: 9

SID: 51463371 EID: EDT: AUFTR: AUFNAHME: 51463371

Seite 1 von 1

Fig. 4. ECG report 3




Fig. 5. ECG report 4




Fig. 6. ECG report 5




Fig. 7. ECG report 6





Fig. 8. ECG report 7




Fig. 9. USG image 2




Fig. 10. USG image 3

“The extra cause of the vaccine complications is not exactly understood, but they are likely due to inflammatory immune system response to components of the vaccine that attack cells and tissue in the body” [14].

Blood clots can form in veins and arteries. Typical locations are in legs and hands, less common are in the abdominal organs or brain [15].

The complications are really rare, as example the incidence of the VITT is observed in 1/100.000 vaccine exposures [16].

4. CONCLUSIONS

The COVID-19 continue to cause significant morbidity and mortality over the world. The COVID-19 vaccines have adverse side effects, which are rare but also sometimes fulminant too.

ETHICAL APPROVAL

As per international standard or university standard written ethical approval has been collected and preserved by the author(s).

CONSENT

As per international standard or university standard, patients' written consent has been collected and preserved by the author(s).

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Hasan K Siddiqi, Peter Libby, Paul M Ridker. COVID-19 - A vascular disease.
2. Alexandra L. Solomon, Elizabeth V. Ratchford, Keith B. Armitage, Jason C. Kovacic. Vascular Disease Patient Information Page: Vascular considerations with COVID-19 vaccines.
3. Meyer AA, Mathews EH, Gous AGS, Mathews MJ. Using a systems approach to explore the mechanisms of interaction between severe Covid-19 and its coronary heart disease complications.
4. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, Cook JR, Nordvig AS, Shalev D, Sehrawat TS, Ahluwalia N, Bikdeli B, Dietz D, Der-Nigoghossian C, Liyanage-Don N, Rosner GF, Bernstein EJ, Mohan S, Beckley AA, Seres DS, Choueiri TK, Uriel N, Ausiello JC, Accili D, Freedberg DE, Baldwin M, Schwartz A, Brodie D, Garcia CK, Elkind MSV, Connors JM, Bilezikian JP, Landry DW, Wan EY. Post-acute COVID-19 syndrome.
5. Carod-Artal FJ. Post-COVID-19 syndrome: epidemiology, diagnostic criteria and pathogenic mechanisms involved.
6. Ludvigsson JF. Case report and systematic review suggest that children may experience similar long-term effects to adults after clinical COVID-19.
7. Farshidfar F, Koleini N, Ardehali H. Cardiovascular complications of COVID-19.
8. Chang WT, Toh HS, Liao CT, Yu WL. Cardiac Involvement of COVID-19: A Comprehensive Review.
9. Schultz NH, Sørvoll IH, Michelsen AE, Munthe LA, Lund-Johansen F, Ahlen MT, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. *N Engl J Med.* 2021;384(22):2124–30.
10. Muir KL, Kallam A, Koepsell SA, Gundabolu K. Thrombotic thrombocytopenia after Ad26. COV2. S vaccination. *N Engl J Med.* 2021;384(20):1964–5.
11. Alih F, Schönborn L, Kohler S, Franke C, Möckel M, Dörner T, et al. Vaccine-induced thrombocytopenia with severe headache. *N Engl J Med.* 2021;385(22):2103–5.
12. Izk JG, Gupta A, Sardar P, Henry BM, Lewin JC, Lippi G, et al. Clinical characteristics and pharmacological management of COVID-19 vaccine-induced immune thrombotic thrombocytopenia with cerebral venous sinus thrombosis: A review. *JAMA Cardiol.* 2021;6(12):1451–60.
13. Luo J, Zhu X, Jian J, Chen X, Yin K. Cardiovascular disease in patients with COVID-19: evidence from cardiovascular pathology to treatment.
14. Soumya RS, Unni TG, Raghu KG. Impact of COVID-19 on the Cardiovascular System: A Review of Available Reports.
15. Agrawal H, Das N, Nathani S, Saha S, Saini S, Kakar SS, Roy P. An Assessment on Impact of COVID-19 Infection in a Gender Specific Manner.
16. Aleksova A, Gagno G, Sinagra G, Beltrami AP, Janjusevic M, Ippolito G, Zumla A, Fluca AL, Ferro F. Effects of SARS-CoV-2 on Cardiovascular System: The Dual Role of Angiotensin-Converting Enzyme 2 (ACE2) as the Virus Receptor and Homeostasis Regulator-Review.

© 2022 Abdo et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
<https://www.sdiarticle5.com/review-history/88468>